Together, GLP-1R, GIPR, and GCGR agonists are expected to see more clinical trial evidence to prove their efficacy and safety in treating obese patients
Supplementary information Supplementary Tables 18 Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
Movement: the paradox that works When you are tired, the last thing you want to do is exercise
Yogurt: Non-fat yogurt is a great cold food for soothing the stomach
People who stop taking Wegovy may regain some of the weight they lost